Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features
| Autor: | Lourdes Florensa, David Roman-Bravo, Marcio Andrade-Campos, Concepción Fernández-Rodríguez, Blanca Espinet, Sara Garcia-Avila, Ana Ferrer, Ivonne Parraga, Luis Colomo, Marta Salido, Leonor Arenillas, Xavier Calvo, Brayan Merchan, Beatriz Bellosillo, Joan Gibert, Sara Montesdeoca, Anna Puiggros, Nieves Garcia-Gisbert |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Myeloproliferative Disorders
Myeloid Neoplasia business.industry Myelodysplastic syndromes Chronic myelomonocytic leukemia Leucèmia Leukemia Myelomonocytic Chronic Genomics Hematology Leucèmia mieloide crònica medicine.disease Peripheral blood Immunophenotyping Leukemia Monocyte count Monocytosis Myelodysplastic Syndromes hemic and lymphatic diseases Immunology medicine Humans business |
| Zdroj: | Blood Adv |
| Popis: | Oligomonocytic chronic myelomonocytic leukemia (OM-CMML) is defined as those myelodysplastic syndromes (MDSs) or myelodysplastic/myeloproliferative neoplasms, unclassifiable with relative monocytosis (≥10% monocytes) and a monocyte count of 0.5 to 94% classical monocytes (MO1s) and CD56 and/or CD2 positivity in peripheral blood monocytes, was similar to overt CMML. The MO1 percentage >94% method showed high accuracy for predicting CMML diagnosis (sensitivity, 90.7%; specificity, 92.2%), even when considering OM-CMML as a subtype of CMML (sensitivity, 84.9%; specificity, 92.1%) in our series of 233 patients (39 OM-CMML, 54 CMML, 23 MDS, and 15 myeloproliferative neoplasms with monocytosis and 102 reactive monocytosis). These results support the consideration of OM-CMML as a distinctive subtype of CMML. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|